Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) gapped down before the market opened on Monday after UBS AG downgraded the stock from an outperform rating to a market perform rating. The stock had previously closed at $55.17, but opened at $61.59. Intercept Pharmaceuticals shares last traded at $62.63, with a volume of 4,941,154 shares.

ICPT has been the subject of several other research reports. Cantor Fitzgerald reiterated an “underweight” rating and issued a $69.00 target price (up previously from $60.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 8th. BMO Capital Markets reiterated an “outperform” rating and issued a $221.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $200.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, September 14th. Jefferies Group LLC reiterated a “buy” rating and issued a $275.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 20th. Finally, Royal Bank Of Canada assumed coverage on Intercept Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $244.00 target price for the company. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Intercept Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $174.93.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 1,434 shares of Intercept Pharmaceuticals stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $121.78, for a total transaction of $174,632.52. Following the sale, the chief executive officer now owns 570,284 shares of the company’s stock, valued at approximately $69,449,185.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Lisa Bright sold 394 shares of Intercept Pharmaceuticals stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $121.33, for a total value of $47,804.02. Following the sale, the insider now directly owns 23,619 shares in the company, valued at approximately $2,865,693.27. The disclosure for this sale can be found here. Insiders have sold a total of 8,013 shares of company stock worth $966,747 in the last ninety days. 4.50% of the stock is owned by company insiders.

A number of institutional investors have recently made changes to their positions in ICPT. Teachers Advisors LLC raised its stake in Intercept Pharmaceuticals by 9.5% during the 4th quarter. Teachers Advisors LLC now owns 15,410 shares of the biopharmaceutical company’s stock valued at $1,674,000 after acquiring an additional 1,339 shares in the last quarter. US Bancorp DE bought a new stake in shares of Intercept Pharmaceuticals in the 1st quarter worth $130,000. Bank of New York Mellon Corp raised its stake in shares of Intercept Pharmaceuticals by 10.2% in the 1st quarter. Bank of New York Mellon Corp now owns 68,302 shares of the biopharmaceutical company’s stock worth $7,725,000 after buying an additional 6,312 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Intercept Pharmaceuticals by 24.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 5,006 shares of the biopharmaceutical company’s stock worth $566,000 after buying an additional 990 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares in the last quarter. 82.19% of the stock is currently owned by hedge funds and other institutional investors.

The company has a 50 day moving average price of $106.75 and a 200-day moving average price of $115.74. The stock’s market cap is $1.58 billion. Intercept Pharmaceuticals also was the target of unusually large options trading on Friday. Stock traders bought 5,053 call options on the company. This represents an increase of 548% compared to the typical daily volume of 780 call options.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, beating the Zacks’ consensus estimate of ($3.62) by $0.16. The firm had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The business’s quarterly revenue was up 459.6% compared to the same quarter last year. During the same period last year, the company earned ($3.14) EPS. On average, analysts forecast that Intercept Pharmaceuticals, Inc. will post ($13.95) earnings per share for the current fiscal year.

WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/25/intercept-pharmaceuticals-inc-icpt-shares-gap-down-after-analyst-downgrade.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.